• Pharmaceutical R&D tax incentives

    Globalization of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. This report explores the impact on R&D tax incentives.

  • Megatrends - Health reimagined

    Health care is embarking on a once-in-a-lifetime transformation. This report explores what the industry needs to do to achieve future success.

  • The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • Life sciences: preparing for big data and analytics

    Many life sciences organizations are not capturing and applying value from analytics in a meaningful way. Gain the edge by harnessing today’s big data insights.

  • Navigating the payer landscape in pharma

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Pulse of the industry - medical technology report 2013

    Facing regulatory pressures, resource constraints, and changing health care industry, the medtech industry must redefine innovation to deliver value for payers and patients. Read more.

  • Cash on prescription 2013

    The 14 leading pharma companies have up to US$40 billion tied up unnecessarily in working capital. What strategies can help companies increase efficiency?

  • Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY - Biopharma in an era of elusive growth

Biopharma in an era of elusive growth

Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.